News stories about FibroGen (NASDAQ:FGEN) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. FibroGen earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.4390809506574 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Shares of FibroGen (NASDAQ FGEN) traded up $0.45 during trading hours on Friday, reaching $42.40. 2,686,872 shares of the company traded hands, compared to its average volume of 628,497. FibroGen has a 12-month low of $19.25 and a 12-month high of $60.15. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16.

Several equities research analysts recently commented on FGEN shares. Jefferies Group reiterated a “buy” rating and set a $75.00 price target on shares of FibroGen in a research note on Tuesday, September 12th. BidaskClub lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Stifel Nicolaus reiterated a “buy” rating and set a $80.00 price target on shares of FibroGen in a research note on Thursday, September 14th. Mizuho started coverage on shares of FibroGen in a research note on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price target on the stock. Finally, ValuEngine lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $65.67.

In other FibroGen news, Director Gerald Lema acquired 3,500 shares of the company’s stock in a transaction on Monday, December 4th. The shares were bought at an average cost of $46.70 per share, for a total transaction of $163,450.00. Following the completion of the purchase, the director now owns 3,500 shares in the company, valued at approximately $163,450. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Thomas B. Neff sold 18,900 shares of FibroGen stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $42.71, for a total transaction of $807,219.00. Following the completion of the transaction, the chief executive officer now owns 3,060,887 shares in the company, valued at $130,730,483.77. The disclosure for this sale can be found here. Insiders have sold a total of 348,346 shares of company stock worth $18,296,630 over the last quarter. 13.60% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/fibrogen-fgen-receives-media-sentiment-rating-of-0-12/1766859.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.